# Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

> **NCT04572165** · — · UNKNOWN · sponsor: **Novo Nordisk A/S** · enrollment: 600000 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Ozempic®
- **DRUG:** Active Comparator
- **DRUG:** Rybelsus®

## Key facts

- **NCT ID:** NCT04572165
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 600000 (ESTIMATED)
- **Last updated:** 2024-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572165, "Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04572165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*